- VIVUS Announces Favorable Markman Ruling in Qsymia(R) Patent Litigation
- VIVUS to Extend Return Date of STENDRA Commercial Rights
- Vivus Reports 2016 First Quarter Financial Results
- VIVUS Announces Date of 2016 First Quarter Business Update and Financial Results Teleconference
- VIVUS Reports Fourth Quarter and Year-End 2015 Financial Results
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.